Bedinvetmab

Brand names: Librela · Active ingredient: Bedinvetmab

In short: LIBRELA is indicated for the control of pain associated with osteoarthritis in dogs.

LabelZoetis Inc.
Label updatedFeb 24, 2025

What is Bedinvetmab used for?

LIBRELA is indicated for the control of pain associated with osteoarthritis in dogs.

âš  Boxed warning (FDA's strongest warning)

User Safety Warnings

Not for use in humans. Keep this and all drugs out of reach of children.For use in dogs only.

Hypersensitivity reactions, including anaphylaxis, could potentially occur in the case of accidental self-injection.

In case of accidental self-injection, seek medical advice immediately and show the package leaflet, vial or carton to the physician.

Pregnant women, women trying to conceive, and breastfeeding women should take extreme care to avoid accidental self-injection.

The importance of Nerve Growth Factor in ensuring normal fetal nervous system development is well-established and laboratory studies conducted on nonhuman primates with human anti-NGF antibodies have shown evidence of reproductive and developmental toxicity.

Bedinvetmab dosage

Always provide the Client Information Sheet and discuss potential adverse drug events with the dog owner prior to administering each injection of LIBRELA .

The minimum target dose of LIBRELA is 0.23 mg/lb (0.5 mg/kg) body weight, administered subcutaneously once a month. Dogs should be dosed by weight range according to the specific dosing information below.

The product does not contain a preservative. The full content of each vial is for single-use only. Once punctured, contents of the vial should be used immediately and any remaining solution should be discarded.

Dogs weighing ≥ 11 lb (≥ 5 kg):

Dogs should be dosed by weight range according to the Dosing Table below (Table 1). Dogs are given the full content of 1 or 2 vials of the appropriate concentration based on body weight. Aseptically withdraw the total dose into a single syringe and administer immediately.

Table1. Dosing Table

Number and Strength (mg/mL) of LIBRELA Vials to be Administered

Dog Body Weight in Pounds (lb) | Dog Body Weight in Kilograms (kg) | 5 mg/mL

orange | 10 mg/mL

blue | 15 mg/mL

green | 20 mg/mL

gold | 30 mg/mL

purple

11-22.1 | 5-10 | 1 vial

22.2-44.1 | 10.1-20 | 1 vial

44.2-66.1 | 20.1-30 | 1 vial

66.2-88.2 | 30.1-40 | 1 vial

88.3-132.3 | 40.1-60 | 1 vial

132.4-176.4 | 60.1-80 | 2 vials

176.5-220.5 | 80.1-100 | 1 vial | 1 vial

220.6-264.6 | 100.1-120 | 2 vials

Dogs < 11 lb:

Aseptically withdraw 0.045 mL/lb (0.1 mL/kg) from a 5 mg/mL vial (orange vial) into a single syringe and administer immediately. Discard the vial after the dose has been withdrawn.

Effectiveness may not be achieved until after the second dose .

Warnings & precautions

Do not take this medicine if: LIBRELA should not be administered to dogs with known hypersensitivity to bedinvetmab.

LIBRELA should not be used in breeding dogs or in pregnant or lactating dogs. Immunoglobulin G class antibodies such as LIBRELA can pass through the placental blood barrier and be excreted in milk. Fetal abnormalities, increased rates of stillbirths and increased postpartum fetal mortality were noted in rodents and primates receiving anti-NGF monoclonal antibodies.

Administration of monoclonal antibodies may be associated with hypersensitivity reactions and delayed hypersensitivity reactions. If anaphylaxis or other hypersensitivity reaction occurs, discontinue use and institute appropriate therapy.

The safe use of this product with other monoclonal antibodies has not been evaluated. Use with caution in dogs with known hypersensitivity to other immunoglobulin therapy.

Evaluations were not made to determine if interactions occurred between LIBRELA and veterinary vaccines.

Treatment with LIBRELA may result in the formation of anti-bedinvetmab antibodies and potentially the loss of product effectiveness .

The safe use of anti-NGF monoclonal antibodies with concurrent nonsteroidal anti-inflammatory drugs (NSAIDs) has not been established in dogs. In human clinical trials, rapidly progressing osteoarthritis (RPOA) has been reported in a small number of patients receiving humanized anti-NGF monoclonal antibody therapy. The incidence of these events increased in human patients receiving NSAID treatment long term in combination with an anti-NGF monoclonal antibody. RPOA has not been characterized or reported in dogs.

The safety and effectiveness of LIBRELA has not been evaluated in dogs less than 12 months of age. …

Bedinvetmab side effects

The safety of LIBRELA was assessed in a masked, controlled 84-day US field study evaluating the effectiveness of LIBRELA for the control of pain associated with osteoarthritis. Enrollment included 272 dogs, 135 dogs treated with LIBRELA and 137 dogs treated with a negative control (sterile saline). The enrolled dogs were at least 1 year of age (1 to 17 years old), weighed between 1.8 to 62.7 kg and were of various breeds or non-purebred. Dogs were dosed at 28-day intervals and received up to three injections. The most common adverse reactions reported during the study are summarized in Table 2 below.

Table 2. Number (%) of Dogs with Adverse Reactions Reported in the US Field Study

Adverse Reaction* | LIBRELA n (%) (Total N = 135) | Negative Control n (%) (Total N = 137)

Urinary tract infection | 15 (11.1) | 11 (8.0)

Bacterial skin infection | 11 (8.1) | 9 (6.6)

Dermatitis | 10 (7.4) | 8 (5.8)

Dermal mass | 8 (5.9) | 5 (3.6)

Erythema | 6 (4.4) | 5 (3.6)

Dermal cyst(s) | 4 (3.0) | 2 (1.5)

Pain on injection | 4 (3.0) | 2 (1.5)

Inappropriate urination** | 4 (3.0) | 1 (0.7)

Histiocytoma | 3 (2.2) | 0 (0.0)

*An adverse reaction may have occurred more than once in a dog; only the first occurrence was counted.** Of these, two dogs treated with LIBRELA were among those reported with a urinary tract infection. …

About this medicine

LIBRELA (bedinvetmab injection) is a sterile injectable solution containing 5, 10, 15, 20, or 30 mg/mL of bedinvetmab in 20 mM histidine buffer pH 5.0 [(0.027% w/v L- histidine and 0.382% w/v histidine HCl monohydrate), 8.5% w/v trehalose dihydrate, 0.005% w/v disodium EDTA dihydrate, 0.01% w/v L-methionine, and 0.1% w/v poloxamer 188]. Bedinvetmab is a canine IgG monoclonal antibody (mAb), in which the variable regions from canine B cell sequence were joined with canine IgG constant sequences, and is expressed through recombinant DNA techniques in Chinese hamster ovary (CHO) cells. Bedinvetmab binds to nerve growth factor (NGF) to reduce NGF’s effects. Such mAbs are commonly referred to as anti-NGF mAbs.

How it works: Bedinvetmab is a recombinant canine monoclonal antibody that binds to nerve growth factor (NGF), reduces NGF binding to the tropomyosin receptor kinase A (TrkA) and p75 neurotrophin receptor (p75NTR) receptors and decreases TrkA signal transduction in cell types involved in pain. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 61c7b4e0-aab6-4cf5-8471-f94be438c758. Read the full official label on DailyMed.

Related medicines

Gabapentin Meloxicam Acetaminophen and Hydrocodone Duloxetine Prednisone Ibuprofen Tramadol Cyclobenzaprine